Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000019.xml
Download PDF
Fortschr Neurol Psychiatr 2020; 88(09): 552-557
DOI: 10.1055/a-1099-9380
DOI: 10.1055/a-1099-9380
Editorial
20 Jahre Experten Meeting Parkinson
Eine Tour d´Horizon durch die Welt der Parkinsonerkrankungen20th Experten Meeting Parkinson
Zusammenfassung
Das Experten Meeting Parkinson ist ein Treffen führender deutschsprachiger Parkinsonexperten, das in wechselnder Besetzung seit 2000 stattfindet und mit dem jüngsten Treffen in Frankfurt 2019 sein 20-jähriges Jubiläum feierte.
Abstract
The Meeting of Parkinson Experts is a meeting of leading German-speaking Parkinson experts, which has been taking place in a changing line-up since 2000. Its 20th anniversary was celebrated with the latest meeting in Frankfurt 2019.
Publication History
Received: 10 January 2020
Accepted: 11 January 2020
Article published online:
06 July 2020
© Georg Thieme Verlag KG
Stuttgart · New York
-
Literatur
- 1 Whone AL, Watts RL, Stoessl AJ. et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54 (Suppl. 1): 93-101.
- 2 Baas H. Dyskinesia in Parkinson’s disease. Pathophysiology and clinical risk factors. J Neurol 2000; 247 (Suppl. 4): IV12-IV16.
- 3 Müngersdorf M, Sommer U, Sommer M. et al. High-dose therapy with ropinirole in patients with Parkinson’s disease. J Neural Transm 2001; 108 (Suppl. 11): 1309-1317.
- 4 Weintraub D. Impulse control disorders in Parkinson’s disease: a 20-year odyssey. Mov Disord 2019; 34 (Suppl. 4): 447-452.
- 5 Jost WH, Braune S. Autonome Regulationsstörungen beim idiopathischen Parkinsonsyndrom. Akt Neurol 2001; 28 (Suppl. 3): S235-S241.
- 6 Krüger R. Genes in familial parkinsonism and their role in sporadic Parkinson’s disease. J Neurol 2004; 251 (Suppl. 6): VI/2-VI/6.
- 7 Junghanns S, Glöckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 6 (Suppl. 6): VI/19-VI/23.
- 8 Wüllner U, Buhmann C, Hilker R. et al. Ropinirole 24-hour Zukunft. Akt Neurol 2007; 34 (Suppl. 1): S18-S20.
- 9 Schapira AH. Ropinirole 24-hour extended release for Parkinson’s disease. Akt Neurol 2007; 34 (Suppl. 1): S15-S17.
- 10 Pahwa R, Stacy MA, Factor SA. et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68 (Suppl. 14): 1108-1115.
- 11 Reichmann H, Cooper J, Rolfe K. et al. Sleep duration and „on“ time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis 2011; 2011: 354760. doi:10.4061/2011/354760. Epub 2011 May 11.
- 12 Jost WH, Buhmann C, Fuchs G. et al. Initial experience with ropinirole PR (prolonged release). J Neurol 2008; 255 (Suppl. 5): 60-63.
- 13 Van Camp G, Flamez A, Cosyns B. et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363 (Suppl. 9416): 1179-1183.
- 14 Reichmann H, Ehret R, Happe S. et al. Kardiale Fibrosen unter Dopaminagonisten – was gibt es Neues?. Akt Neurol 2007; 34 (Suppl. 1): 521-524.
- 15 Jost WH, Leupold CS. Grundlagen der Pflasterapplikation von Wirkstoffen beim Parkinson-Syndrom. Akt Neurol 2009; 36 (Suppl. 4): S288-S292.
- 16 Trenkwalder C, Kies B, Rudzinka M. et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26 (Suppl. 1): 90-99.
- 17 Respondek G, Decker S, Steinmeyer L. et al. Differentialdiagnosen der Parkinson-Krankheit: aktuelle Konsensuskriterien und Ausblicke. Fortschr Neurol Psychiat 2010; 78 (Suppl. 1): S8-S15.
- 18 Höglinger GU, Respondek G, Stamelou M. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017; 32 (Suppl. &): 853-864.
- 19 Antonini A, Jost WH. Duodentale levodopa and apomorphine infusion for motor complications in advanced Parkinson’s disease. Fortschr Neurol Psychiatr 2018; 86: S5-S9.
- 20 Yilmaz R, Hopfner F, van Eimeren T. et al. Biomarkers of Parkinson’s disease: 20 years later. J Neural Transm 2019; 126 (Suppl. 7): 803-813.
- 21 Riederer P, Berg D, Casadei N. et al. α-Synuclein in Parkinson’s disease: causal or bystander?. J Neural Transm 2019; 126 (Suppl. 7): 815-840.
- 22 Braak H, Del Tredici K, Bratzke H. et al. Staging of the intracebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl. 3): III/1-III/5.